Skip to main content

Galectin Therapeutics Inc 10-Q for FY2026 Q3

Galectin Therapeutics Inc (GALT)

10-Q 2026-11-16 For: 2026-09-30
View Original
Added on November 16, 2026

About this 10-Q

Galectin Therapeutics Inc filed this 10-Q on November 16, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

Galectin Therapeutics said FDA agreed on the primary endpoint and regulatory path for potential full approval of belapectin in MASH cirrhosis with portal hypertension; it filed a Phase 3 protocol in the third quarter of 2026 and is seeking partners. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Net loss
$3.53M
compared with a net loss of $8.18M a year earlier
Diluted EPS
-$0.04
compared with -$0.13 a year earlier